Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTRI/2023/12/060636
CTRI/2023/12/060636Not yet recruitingPhase 3

A RANDOMISED SINGLE-BLIND,TWO- ARM CLINICAL STUDY COMPARING THE EFFICACY, SAFETY OF STANDARD UNANI FORMULATION WITH CLOTRIMAZOLE 1% CREAM IN THE TREATMENT OF QOOBA(TINEA CRURIS). - NI

PG Department of Moalijat0 sites0 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 3
Status
Not yet recruiting
Sponsor
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • •Age between 12 months - 80 years
  • •Clinically diagnosed patients of qooba (times cruris)
  • •Patients who have signed the informed consent form

Exclusion Criteria

  • •Patients suffering from concomitant diseases like psoriasis, eczema
  • •Patients suffering from infection diseases
  • •Patients suffering from severe systemic and metabolic diseases
  • •Diabetic and hypertensive patients
  • •STD diseases diagnosed patients
  • •Pregnant and lactating women

Investigators

Sponsor
PG Department of Moalijat

Similar Trials

Not yet recruiting
Phase 3
To study the effect of unani medicine in piles.
CTRI/2023/12/060627Government Nizamia Tibbi College and General Hospital
Not yet recruiting
Phase 2
A clinical study on the management of type 2 Diabetes Mellitus with Nisha katakadi Niruha basti and Dhanvantaram ghritha Matrabasti followed by Saptachakra Kashaya as shamanoushadi with two parellel groups A and B respctively with which only patient is blinded.
CTRI/2019/07/020314Rajiv Gandhi University of Health Sciences Bengaluru
Not yet recruiting
Phase 1
Oral medicine trial for COVID 19
CTRI/2020/09/027616RGUHS Bangalore
Active, not recruiting
Not Applicable
sing Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) PatientsMedDRA version: 17.1Level: PTClassification code 10028245Term: Multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersMultiple Sclerosis
EUCTR2013-001439-34-DEGenzyme Corporation1,000
Active, not recruiting
Phase 1
sing Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) PatientsMultiple Sclerosis
EUCTR2013-001439-34-ESGenzyme Corporation1,001